EUVIMEDDécouvrir EUVIMED
Open access · CC BY-NC-ND 4.0

Rate of Hearing Loss in Platinum‐Naïve Patients Receiving Immune Checkpoint Inhibitors

Kaitlyn A Brooks iD, Christopher G Gidley, Olivia Grimley, Catherine Wang, Shirin Jivani, Dianna Roberts, Aung Naing iD, Jack Phan iD, Katherine Hutcheson iD, Xin Wang iD, Paul W Gidley iD, Marc-Elie Nader iD

Otolaryngology–Head and Neck Surgery · 2026-05 · 174 (5) · 1289-1297

DOI: 10.1002/ohn.70191 ↗

At a glance

Journal article in Otolaryngology–Head and Neck Surgery, published online on 2026-03-07. Written by Kaitlyn A Brooks and 11 co-authors. Institution: Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Major MEDLINE topics: Hearing Loss, Immune Checkpoint Inhibitors, Ototoxicity. 36 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

RésuméSubjectsRéférences bibliographiquesCiteRelated studies

Abstract (original language)

Objective

Hearing loss from immune checkpoint inhibitors (ICIs) has been documented in case reports and case series. We present the largest retrospective study investigating the rate of ICI‐related ototoxicity in a monitored cohort of platinum‐naïve patients. Study Design Retrospective cohort study.

Setting

Tertiary‐care center.

Methods

Patients treated with ICI between January 1, 2017, and December 31, 2022, with baseline and post‐treatment audiograms, were included. Patients with a history of platinum‐based chemotherapy were excluded. Demographics, oncologic diagnosis, ICI treatment details, and temporal bone irradiation (TBRT) were recorded. Audiometric thresholds were compared before and after ICI therapy. The primary outcome measure was a change in hearing as defined by the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE). Secondary outcome measures included changes in hearing using the American Speech‐Language‐Hearing Association (ASHA) and TUNE criteria.

Results

Among 15,390 ICI recipients, 29 platinum‐naïve patients met the inclusion criteria. Six of 29 patients (20.7%) experienced a CTCAE grade 1 or higher hearing loss. The proportions of hearing loss as defined by ASHA and TUNE criteria were 44.8% and 27.6%, respectively. The length of time between baseline and follow‐up audiograms was significantly longer among patients with hearing loss (mean difference [days]: CTCAE: 590.3, P < .01; ASHA: 280.9, P = .05; and TUNE: 122.1, P = .46). No other potential covariates believed to be confounders were significantly associated with the outcome.

Conclusion

A significant proportion of our monitored platinum‐naïve ICI patients met hearing‐loss criteria. Prospective studies with standardized audiologic surveillance are needed to further quantify the true incidence of ICI ototoxicity.

Subjects

MeSH terms (MEDLINE)

Hearing LossImmune Checkpoint InhibitorsOtotoxicityRetrospective StudiesAudiometryNeoplasmsIncidenceHumansMaleFemaleMiddle AgedAgedAged, 80 and over

Author keywords

hearing lossimmune checkpoint inhibitorsimmunotherapyototoxicity

Substances

Immune Checkpoint Inhibitors

Authors and institutions

  • Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

ORCID profiles: Kaitlyn A Brooks, Aung Naing, Jack Phan, Katherine Hutcheson, Xin Wang, Paul W Gidley, Marc-Elie Nader

Cite

APA

Brooks, K. A., Gidley, C. G., Grimley, O., Wang, C., Jivani, S., Roberts, D., Naing, A., Phan, J., Hutcheson, K., Wang, X., Gidley, P. W., & Nader, M. E. (2026). Rate of Hearing Loss in Platinum‐Naïve Patients Receiving Immune Checkpoint Inhibitors. Otolaryngology–Head and Neck Surgery, 174(5), 1289-1297. https://doi.org/10.1002/ohn.70191

Vancouver

Brooks KA, Gidley CG, Grimley O, Wang C, Jivani S, Roberts D, et al. Rate of Hearing Loss in Platinum‐Naïve Patients Receiving Immune Checkpoint Inhibitors. Otolaryngology–Head and Neck Surgery. 2026;174(5):1289-1297. doi:10.1002/ohn.70191

BibTeX
@article{Brooks2026,
  author = {Brooks, Kaitlyn A and Gidley, Christopher G and Grimley, Olivia and Wang, Catherine and Jivani, Shirin and Roberts, Dianna and Naing, Aung and Phan, Jack and Hutcheson, Katherine and Wang, Xin and Gidley, Paul W and Nader, Marc-Elie},
  title = {Rate of Hearing Loss in Platinum‐Naïve Patients Receiving Immune Checkpoint Inhibitors},
  journal = {Otolaryngology–Head and Neck Surgery},
  year = {2026},
  volume = {174},
  number = {5},
  pages = {1289--1297},
  doi = {10.1002/ohn.70191}
}
Start for free →